ADAM17 and colorectal carcinoma: These observations are consistent with previously published data that targeting ADAM10 (Atapattu et al., 2016), ADAM17 (Kyula et al., 2010), or ADAM19 (Zhang et al., 2015) with small-molecule compounds attenuates CRC development and progression in mice.